NCT00683241View on ClinicalTrials.gov

A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Ovarian CancerPeritoneal Cancer
Interventions
BIOLOGICAL

DCVac-L

Subjects will receive three doses of intradermal vaccination with \~5-10 x 106 dendritic cells (DCVax-L) on days 0, 14 and 28

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

Northwest Biotherapeutics
All Listed Sponsors
collaborator

Northwest Biotherapeutics

INDUSTRY

collaborator

University of California, San Francisco

OTHER

lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT00683241 - A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter